RT Journal
A1 Mitka M
T1 FDa approves a statin therapy for some
JF JAMA
JO JAMA
YR 2010
FD April 7
VO 303
IS 13
SP 1242
OP 1243
DO 10.1001/jama.2010.342
UL http://dx.doi.org/10.1001/jama.2010.342
AB 
On February 8, the FDA announced that rosuvastatin is now indicated for the primary prevention of cardiovascular disease in men aged 50 years or older and women aged 60 years or older who meet certain criteria. These include an elevated level (2 mg/L or higher) of high-sensitivity C-reactive protein (hsCRP, a nonspecific inflammatory biomarker) and at least 1 additional cardiovascular risk factor, such as hypertension, a low level of high-density lipoprotein cholesterol, smoking, or a family history of premature heart disease. The agency had previously approved rosuvastatin for the purpose of lowering cholesterol and triglycerides in combination with diet and exercise in patients with high levels of cholesterol and/or triglycerides and slowing the progression of atherosclerosis.